

Figure 1. The volume of interest for magnetic resonance spectroscopy measurements was positioned at the center of the multifidus muscle (Mm), as indicated on the T2-weighted image at the L4/5 level.

tion and one of the most serious physiological issues in the world⁸⁻¹⁰. Recently, the mechanism of LBP has been elucidated^{11,12}. Trunk muscles are important for normal spinal function and are etiologically significant in LBP^{13,14}. In particular, the multifidus muscle (Mm) provides two-thirds of spinal segmental stability¹⁵ and is important for maintaining spinal alignment¹⁶. The evaluation of the Mm function forms part of the clinical assessment of LBP patients¹⁷, and changes in Mm function are related to the outcome of conservative therapy^{13,18}. The measurement of lumbar paraspinal muscle morphology using magnetic resonance imaging (MRI) is reportedly effective for the determination of atrophy and fat infiltration¹⁹. Recently, in addition to morphological assessments, muscles have been evaluated using MRI with the multipoint Dixon technique^{20,21} and magnetic resonance spectroscopy (MRS)^{22,23}. MRS analysis of muscle physiology has facilitated detailed analyses of muscular fat masses by recording the concentration of extramyocellular lipids (EMCLs) and intramyocellular lipids (IMCLs), which in turn are useful for the identification of fatty degeneration²⁴⁻³⁰. In our previous study, IMCL using MRS analyses in the Mm of chronic LBP (CLBP) patients was significantly higher than that in control subjects³¹⁻³³. In addition, we identified the associations of spino-pelvic alignment (lumbar lordosis and sagittal vertical axis) with the IMCL of the Mm in CLBP³². The purpose of this study was to analyze the EMCL and IMCL of the Mm using MRS in CLBP and identify the possible correlations with age, body mass index (BMI), LBP visual analog scale (VAS), cross-sectional area (CSA), and fat infiltration of the Mm.

Materials and Methods

The Hospital Board of Ethics approved this study, and written informed consent was obtained from all the partici-

pants before study initiation.

Participants

Subjects comprised patients with nonspecific CLBP, which was defined as experiencing pain, stiffness, and discomfort in the lower back from the 12th rib to the lumbar or lumbosacral area and had persisted for more than 3 months and whose symptoms had persisted despite conservative treatments. We excluded patients with neurological symptoms of the lower leg or obvious instability, which could be identified as a pain generator that caused CLBP and could be improved with surgical treatment. The exclusion criteria included the following: (i) systemic inflammatory disease; (ii) neurological disorder; (iii) prior spine surgery; (iv) neoplasm, infection, or acute trauma; (v) spinal deformities such as spondylolisthesis with obvious instability, which meant sagittal translation of more than 3 mm, segmental motion of more than 20°, or posterior opening of more than 5° on flexion/extension radiographs or scoliosis (>10°); and (vi) diabetes, hypertriglyceridemia, or other metabolic and endocrine disorders. Eighty patients (32 men and 48 women; mean age, 64.7 ± 1.3 years; range, 22-83 years) fulfilled the diagnostic criteria. The numbers of men and women for each age group were 5 and 5, respectively, for < 40 years; 7 and 12, respectively, for the 50s; 8 and 12, respectively, for the 60s; 8 and 13, respectively, for the 70s; and 4 and 6, respectively, for the 80s. All subjects underwent MRI of the lumbar spine and completed the LBP VAS (0-100 mm). We calculated the BMI using the self-reported body weight (kg) divided by the height squared (m²) to determine the prevalence of obesity associated with the fat content.

MRI protocol

We used the previously described MRI protocol³¹⁻³³. In brief, the Signa HDx 1.5T MRI system (GE Healthcare, Milwaukee, WI, USA) with a spine coil was used to obtain the T2-weighted sagittal and transverse MR images. Using these images, the proton MRS volume of interest (VOI) was positioned at the center of the Mm at L4/5 for the right side (Fig. 1). Single-voxel point-resolved spectroscopy sequence was performed with the following parameters: repetition time (TR), 2000 ms; echo time (TE), 35 ms; average number of signals, 64; VOI size, 15 × 15 × 15 mm (3.4 mL); and acquisition time, 164 s.

Measurement of CSA and fat infiltration

The CSA and fat-infiltrated area were measured by axial T2-weighted MRI. We measured the right Mm at L4/5 (same level and side as for MRS). CSA was defined by manually tracing the fascial border of the Mm (Fig. 2a), as previously described³⁴. The regions of interest were analyzed for the areas and histograms of signal intensity using digitized image-processing software (Image J; National Institutes of Health, Bethesda, MD, USA). The percentage of fat-infiltrated area was measured using a pseudo-coloring




Figure 2. Axial T2-weighted magnetic resonance imaging was performed to measure the cross-sectional area (CSA) and fat infiltration rate of the multifidus muscle (Mm) at the intervertebral level L4 through L5.

(a) The CSA of the right Mm was measured using the transverse T2-weighted image.

(b) The fat infiltration of the Mm was measured using the transverse T2-weighted image with Image J.




Figure 3. Proton magnetic resonance spectrum of the Mm analyzed using the LC-Model software.

The following metabolites were identified: intramyocellular lipids (IMCLs) (-CH₂) methylene protons at 1.3 ppm; extramyocellular lipids (EMCLs) (-CH₂) methylene protons at 1.5 ppm.

method, according to which bright pixels of fat tissue were colored red using the pseudo-coloring tool of the software. Subsequently, the percentage of the red area in the muscle compartment was calculated (Fig. 2b). Then, we calculated the corrected CSA as the actual measurement CSA (cm²) divided by the height squared (m²) in order to standardize by body stature. To classify fat infiltration of the Mm, we used a three-grade visual scale adapted as previously reported³⁵:

“Grade 0” for estimates of 0%-10% fat within the muscle, “Grade 1” for 10%-50% fat, and “Grade 2” for > 50% fat.

All muscle measurements were performed by two investigators (Observer 1: IO; Observer 2: HT) who were blinded to the patients’ clinical details. The intra- and inter-rater reliabilities for the measurement of the paraspinal muscle were assessed, yielding similar results (Pearson’s correlation coefficient; 0.92-0.93, 0.91-0.92). Finally, we adopted the data

of Observer 1.

Analysis of MRS data

Analysis of MRS data was performed by a method previously described³¹⁻³³. The spectral data obtained were used to measure IMCL and EMCL using the LCModel software

Table 1. Pearson's Correlation Coefficient of Age, BMI, CSA, and VAS with the EMCL and IMCL of the Mm.

	EMCL		IMCL	
	r	p	r	p
Age	0.33	<0.01	-0.02	0.83
BMI	0.42	<0.01	-0.07	0.51
CSA	-0.61	<0.01	-0.14	0.24
VAS	-0.06	0.53	0.43	<0.01

IMCL: intramyocellular lipid; EMCL: extramyocellular lipid; Mm: multifidus muscle; BMI: body mass index; CSA: cross-sectional area; VAS: visual analog scale

(Stephen Provencher, Inc., Oakville, Ontario, Canada). Data were transferred from the scanners to a Linux workstation, and metabolite quantification was performed by eddy current correction and water scaling. Data for IMCL (1.3 ppm) and EMCL (1.5 ppm) corresponding to the methylene protons were used for statistical analyses. Assessments of IMCL and EMCL were automatically scaled to an unsuppressed water peak (4.7 ppm) and expressed in institutional units. These data are displayed graphically with the chemical shift along the x-axis, allowing identification of the metabolites. The peak intensity is plotted on the y-axis (Fig. 3). We excluded subjects with Mm over 15% of the %SD of EMCL or IMCL on the LCModel.

Statistical analyses

We checked the gender differences for each age group with the chi-square test. We investigated the gender differences concerning CSA, EMCL, and IMCL of the Mm with the Mann-Whitney U-test. We analyzed the possible correlations of age, BMI, LBP VAS, CSA, and fat infiltration of




Figure 4. Comparisons of the gender difference concerning CSA (a), EMCL (b), and IMCL (c) of the Mm.

CSA were larger in the male group; EMCL was higher in the female group, and there was no significant difference between the female and male groups for IMCL.

Data are shown as the means±standard error of the mean.

$p < 0.01$ female versus male: Mann-Whitney U-test.




Figure 5. Comparisons of the CSA, fat infiltration, EMCL, and IMCL of the Mm among the five groups divided by age.

(a) The CSA of the Mm decreased with age; the CSA in subjects >60 years significantly decreased than in those <50 years.

(b) The fat infiltration rate increased with age; the fat infiltration rate in subjects >70 years significantly decreased than in those <60 years.

(c) The EMCL of the Mm decreased with age; the EMCL in subjects >80 years significantly decreased than in those <50 years.

(d) The IMCL of the Mm was not associated with age.

Data are shown as the means \pm standard error of the mean.

* $p < 0.01$: one-way factorial measures of analysis of variance (ANOVA) with *post hoc* testing performed using the Bonferroni method.

the Mm with the EMCL and IMCL of the Mm using Pearson's correlation coefficient analyses. The subjects were divided into the following five groups as per their age— < 40 years, 50s, 60s, 70s, and 80s (more than 10 subjects in each group)— to identify the BMI, CSA fat infiltration, EMCL, and IMCL of the Mm by age using one-way factorial measures of analysis of variance (ANOVA) with the *post hoc* testing performed using the Bonferroni method. We analyzed the EMCL and IMCL of the Mm using the fat infiltration classification with one-way ANOVA and the Tukey-Kramer test among the three experimental groups. A probability value of < 0.05 indicated statistical significance. All the numerical data are expressed as means \pm standard error of the mean (SEM).

Results

As shown in Table 1, there was a significant positive correlation of EMCL with age ($r = 0.33$, $p < 0.01$), BMI ($r = 0.42$, $p < 0.01$), and fat infiltration ($r = 0.52$, $p < 0.01$). There was a significant negative correlation of EMCL with CSA ($r = -0.61$, $p < 0.01$). There were no significant correlations between EMCL and VAS score ($r = -0.06$, $p = 0.53$). There were no significant correlations of IMCL with age ($r = -0.02$, $p = 0.83$), BMI ($r = -0.07$, $p = 0.51$), and CSA ($r = -0.14$, $p = 0.24$). There was a significant positive correlation of IMCL and VAS score ($r = 0.43$, $p < 0.01$).

There were no statistically significant gender differences for each age group ($p = 0.97$). CSA was larger in the male group (Fig. 4a), EMCL was higher in the female group (Fig. 4b), and there was no significant difference (Fig. 4c) between the female and male groups for IMCL.




Figure 6. Comparisons of the EMCL and IMCL of the Mm among the three groups classified by the fat infiltration classification.

(a) CSA reduced significantly with fat infiltration grade.

(b) EMCL increased significantly with fat infiltration grade.

(c) IMCL was not associated with fat infiltration grade.

Data are shown as the means \pm standard error of the mean.

* $p < 0.01$: ANOVA and the Tukey-Kramer test.

The CSA of the Mm decreased with age; CSA in subjects ≥ 60 years decreased significantly than in those < 50 years (Fig. 5a). The fat infiltration rate increased with age and decreased significantly in subjects ≥ 70 years than in those < 60 years (Fig. 5b). The EMCL of the Mm decreased with age; EMCL in subjects ≥ 80 years significantly decreased than in those < 50 years (Fig. 5c). The IMCL of the Mm was not associated with age (Fig. 5d).

According to the fat infiltration classification, CSA reduced significantly with fat infiltration grade (Fig. 6a), and EMCL increased significantly with fat infiltration grade (Fig. 6b). In contrast, IMCL was not associated with fat infiltration grade (Fig. 6c).

Discussion

Aging is associated with an increased risk of problems related to the locomotor system. Rosenberg³⁶⁾ first defined the

concept of sarcopenia as a condition involving a loss of muscle mass and strength due to age. Then, some consensus on the definition and diagnosis of sarcopenia from the European Working Group on Sarcopenia in Older People¹⁾, the International Working Group on Sarcopenia²⁾, and the Asian Working Group for Sarcopenia³⁾ was proposed. Sarcopenia is a common problem and has been well recognized as one of the relevant factors concerning a prevalence of disability³⁷⁾; however, no broadly accepted clinical measurement method has been established so far. Several methods can be used to assess the muscle mass.

The CSA and fat content used as indexes of muscle degeneration were estimated by ultrasonography³⁸⁾, computed tomography (CT)³⁹⁾, and MRI¹⁹⁾. MRI is valuable for evaluating the muscles because of its good contrast of soft tissue. In recent years, several studies have revealed degenerative disorders of the paraspinal muscles using a variable approach related to fatty degeneration^{20,22,40,41)}. Most of these

studies used the fat fraction of the multipoint Dixon technique to evaluate fatty degeneration; however, studies using MRS comprehensively estimated the degeneration as the total amount of fat content. In the present study, the adipose tissue of the Mm was excellently separated as EMCL and IMCL.

In this cross-sectional study, we analyzed the EMCL and IMCL of the Mm using MRS to identify the possible correlations with atrophy and fat infiltration of the Mm. Quantitative analyses of the EMCL and IMCL in the Mm revealed correlations of EMCL with age, BMI, CSA, and fat infiltration and correlations of IMCL with LBP VAS score. EMCL locates extracellular adipose tissue around the muscle cells and provides long-term energy storage. We noted the association between EMCL and CSA as an index of muscle atrophy as stated in past reports^{25,42}. In addition, EMCLs are thought to be metabolically inactive lipid deposits related to reduced functionality such as a sedentary lifestyle and lack of exercise^{26,27}. Muscle weakness is related to EMCL storage interfering with sufficient muscle nutrition^{24,27}. In the present study, increased EMCL levels could correlate with aging and fatty degeneration. Therefore, we believe that EMCLs can be used as a quantitative and reasonable index for evaluating the Mm degeneration associated with aging. In contrast, IMCLs are stocked as intramuscular lipid droplets in the skeletal muscle cells. They exist near the mitochondria, probably related to oxidative metabolism^{25,30}, and serve as a rapidly usable source of energy for muscular fatty acid oxidation^{26,30,43}. IMCLs are reportedly related to the storage of free fatty acids and insulin resistance, and increased IMCL concentrations have been observed in type 2 diabetic patients^{26,44}. An association has been observed between IMCL and LBP; therefore, it is possible that the mitochondrial activity of the Mm is impaired, resulting in an increased level of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor- α , in the Mm of CLBP patients^{45,46}. IMCL could be an effective index of CLBP.

This study has several limitations. First, we do not assess the daily physical activity of the patients. Daily activity might influence the concentration of EMCL and IMCL. Second, this was a cross-sectional study; a longitudinal study design would have been a better choice. Third, we evaluated only CLBP. We should perform detailed questioning and physical examination to accurately assess CLBP.

In summary, we analyzed the EMCL and IMCL of the Mm using the MRS in CLBP and identified the possible correlations with LBP VAS, CSA, and fat infiltration of the Mm in this cross-sectional and comparative study. The CSA of the Mm decreased with age, whereas the fat infiltration rate increased with age. Quantitative analyses of the EMCL and IMCL in the Mm revealed correlations of EMCL with age, BMI, CSA, and fat infiltration and correlations of IMCL with LBP VAS score. This may suggest that EMCL could evaluate the Mm degeneration associated with aging, and IMCL could become an effective objective indicator of CLBP.

Conflicts of Interest: The authors declare that there are no relevant conflicts of interest.

Sources of Funding: The project was funded by AOSpine Research Grant and the Japan Osteoporosis Foundation.

Acknowledgement: The project was funded by AOSpine Research Grant and the Japan Osteoporosis Foundation. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions: Izaya Ogon wrote and prepared the manuscript, and all of the authors participated in the study design. All authors have read, reviewed, and approved the article.

References

1. Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age Ageing*. 2014;43(6):748-59.
2. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. *J Am Med Dir Assoc*. 2011;12(4):249-56.
3. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*. 2014;15(2):95-101.
4. Kim JE, Lee YH, Huh JH, et al. Early-stage chronic kidney disease, insulin resistance, and osteoporosis as risk factors of sarcopenia in aged population: the fourth Korea National Health and Nutrition Examination Survey (KNHANES IV), 2008-2009. *Osteoporos Int*. 2014;25(9):2189-98.
5. Psutka SP, Carrasco A, Schmit GD, et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. *Cancer*. 2014;120(18):2910-8.
6. Bryant RV, Ooi S, Schultz CG, et al. Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2015;41(9):895-906.
7. Tarantino U, Piccirilli E, Fantini M, et al. Sarcopenia and fragility fractures: molecular and clinical evidence of the bone-muscle interaction. *J Bone Joint Surg Am*. 2015;97(5):429-37.
8. Deyo RA, Weinstein JN. Low back pain. *N Engl J Med*. 2001;344(5):363-70.
9. Hurwitz EL, Morgenstern H. The effects of comorbidity and other factors on medical versus chiropractic care for back problems. *Spine*. 1997;22(19):2254-63.
10. Shekelle PG, Markovich M, Louie R. An epidemiologic study of episodes of back pain care. *Spine*. 1995;20(15):1668-73.
11. Kikuchi S. The recent trend in diagnosis and treatment of chronic low back pain. *Spine Surg Relat Res*. 2017;1(1):1-6.
12. Ohtori S, Miyagi M, Inoue G. Sensory nerve ingrowth, cytokines, and instability of discogenic low back pain: a review. *Spine Surg Relat Res*. 2018;2(1):11-7.
13. Cholewicki J, Panjabi MM, Khachatryan A. Stabilizing function of trunk flexor-extensor muscles around a neutral spine posture. *Spine*. 1997;22(19):2207-12.

14. Sakai Y, Ito S, Hida T, et al. Low back pain in patients with lumbar spinal stenosis - hemodynamic and electrophysiological study of the lumbar multifidus muscles. *Spine Surg Relat Res.* 2017;1(2):82-9.
15. Wilke HJ, Wolf S, Claes LE, et al. Stability increase of the lumbar spine with different muscle groups. A biomechanical in vitro study. *Spine.* 1995;20(2):192-8.
16. Takemitsu Y, Harada Y, Iwahara T, et al. Lumbar degenerative kyphosis. Clinical, radiological and epidemiological studies. *Spine.* 1988;13(11):1317-26.
17. Hebert JJ, Koppenhaver SL, Teyhen DS, et al. The evaluation of lumbar multifidus muscle function via palpation: reliability and validity of a new clinical test. *Spine J.* 2015;15(6):1196-202.
18. Fritz JM, Koppenhaver SL, Kawchuk GN, et al. Preliminary investigation of the mechanisms underlying the effects of manipulation: exploration of a multivariate model including spinal stiffness, multifidus recruitment, and clinical findings. *Spine.* 2011;36(21):1772-81.
19. Cheung KM, Karppinen J, Chan D, et al. Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals. *Spine.* 2009;34(9):934-40.
20. Yanik B, Keyik B, Conkbayir I. Fatty degeneration of multifidus muscle in patients with chronic low back pain and in asymptomatic volunteers: quantification with chemical shift magnetic resonance imaging. *Skeletal Radiol.* 2013;42(6):771-8.
21. Paalanne N, Niinimäki J, Karppinen J, et al. Assessment of association between low back pain and paraspinal muscle atrophy using opposed-phase magnetic resonance imaging: a population-based study among young adults. *Spine.* 2011;36(23):1961-8.
22. Fischer MA, Nanz D, Shimakawa A, et al. Quantification of muscle fat in patients with low back pain: comparison of multi-echo MR imaging with single-voxel MR spectroscopy. *Radiology.* 2013;266(2):555-63.
23. Mengiardi B, Schmid MR, Boos N, et al. Fat content of lumbar paraspinal muscles in patients with chronic low back pain and in asymptomatic volunteers: quantification with MR spectroscopy. *Radiology.* 2006;240(3):786-92.
24. Boesch C, Machann J, Vermathen P, et al. Role of proton MR for the study of muscle lipid metabolism. *NMR Biomed.* 2006;19(7):968-88.
25. Boesch C. Musculoskeletal spectroscopy. *J Magn Reson Imaging.* 2007;25(2):321-38.
26. Srikanthan P, Singhal A, Lee CC, et al. Characterization of intramyocellular lipids using 2D localized correlated spectroscopy and abdominal fat using MRI in type 2 diabetes. *Magn Reson Insights* 2012;5:29-36.
27. Velan SS, Said N, Durst C, et al. Distinct patterns of fat metabolism in skeletal muscle of normal-weight, overweight, and obese humans. *Am J Physiol Regul Integr Comp Physiol.* 2008;295(4):R1060-5.
28. Jucker BM, Schaeffer TR, Haimbach RE, et al. Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study. *Metabolism.* 2003;52(2):218-25.
29. Boesch C, Kreis R. Observation of intramyocellular lipids by ¹H-magnetic resonance spectroscopy. *Ann N Y Acad Sci.* 2000;904(1):25-31.
30. Schrauwen-Hinderling VB, Hesselink MK, Schrauwen P, et al. Intramyocellular lipid content in human skeletal muscle. *Obesity.* 2006;14(3):357-67.
31. Takashima H, Takebayashi T, Ogon I, et al. Evaluation of intramyocellular and extramyocellular lipids in the paraspinal muscle in patients with chronic low back pain using MR spectroscopy: preliminary results. *Br J Radiol.* 2016;89(1024):20160136.
32. Ogon I, Takebayashi T, Takashima H, et al. Magnetic resonance spectroscopic analysis of multifidus muscles lipid content and association with spinopelvic malalignment in chronic low back pain. *Br J Radiol.* 2017;90(1073):20160753.
33. Takashima H, Takebayashi T, Ogon I, et al. Analysis of intra and extramyocellular lipids in the multifidus muscle in patients with chronic low back pain using MR spectroscopy. *Br J Radiol.* 2018;91(1083):20170536.
34. Takayama K, Kita T, Nakamura H, et al. New predictive index for lumbar paraspinal muscle degeneration associated with aging. *Spine.* 2016;41(2):E84-90.
35. Kjaer P, Bendix T, Sorensen JS, et al. Are MRI-defined fat infiltrations in the multifidus muscles associated with low back pain? *BMC Med* 2007;5(1):2.
36. Rosenberg I. Summary comments. *Am J Clin Nutr.* 1989;50(5):1231-3.
37. Landi F, Calvani R, Cesari M, et al. Sarcopenia: an overview on current definitions, diagnosis and treatment. *Curr Protein Pept Sci.* 2018;19(7):633-8.
38. Hebert JJ, Koppenhaver SL, Parent EC, et al. A systematic review of the reliability of rehabilitative ultrasound imaging for the quantitative assessment of the abdominal and lumbar trunk muscles. *Spine.* 2009;34(23):E848-56.
39. Danneels LA, Vanderstraeten GG, Cambier DC, et al. CT imaging of trunk muscles in chronic low back pain patients and healthy control subjects. *Eur Spine J.* 2000;9(4):266-72.
40. Wan Q, Lin C, Li X, et al. MRI assessment of paraspinal muscles in patients with acute and chronic unilateral low back pain. *Br J Radiol.* 2015;88(1053):20140546.
41. D'Hooge R, Cagnie B, Crombez G, et al. Increased intramuscular fatty infiltration without differences in lumbar muscle cross-sectional area during remission of unilateral recurrent low back pain. *Man Ther.* 2012;17(6):584-8.
42. Dahlqvist JR, Vissing CR, Hedermann G, et al. Fat replacement of paraspinal muscles with aging in healthy adults. *Med Sci Sports Exerc.* 2017;49(3):595-601.
43. Wijsman CA, van Opstal AM, Kan HE, et al. Proton magnetic resonance spectroscopy shows lower intramyocellular lipid accumulation in middle-aged subjects predisposed to familial longevity. *Am J Physiol Endocrinol Metab.* 2012;302(3):E344-8.
44. Lawrence JC, Gower BA, Garvey WT, et al. Relationship between insulin sensitivity and muscle lipids may differ with muscle group and ethnicity. *Open Obes J.* 2010;2:137-44.
45. Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. *Acta Physiol.* 2006;186(1):5-16.
46. Amouzou C, Breuker C, Fabre O, et al. Skeletal muscle insulin resistance and absence of inflammation characterize insulin-resistant grade I obese women. *PLoS One.* 2016;11(4):e0154119.

Spine Surgery and Related Research is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).